News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Oscar Tahuahua: Efficacy and Safety of Larotrectinib as First-Line Treatment for Patients with TRK Fusion Cancer
Oscar Tahuahua/X
May 25, 2025, 08:18

Oscar Tahuahua: Efficacy and Safety of Larotrectinib as First-Line Treatment for Patients with TRK Fusion Cancer

Oscar Tahuahua, Medical Oncology fellow at the National Cancer Institute of Mexico, posted on X:

“Larotrectinib as 1L for TRK fusion cancers (n=101)

  • ORR 77%, CR/pCR 47%, PFS 61 mo, 5yr OS 76%.
  • ORR 90% in children, 68% in adults. Best in locally advanced (ORR 90%). Mostly grade 1–2 AEs.
  • Wait and see-safe in pediatrics, with successful rechallenge.”

Title: Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer

Authors: D.S. Hong, R.-H. Xu, L. Shen, M.P. Dierselhuis, D. Orbach, R. McDermott, A. Italiano, M. Tahara, V. Bernard-Gauthier, N. Neu, C.E. Mussi, E. De La Cuesta, T.W. Laetsch, A. Drilon

Read The Full Article at ESMO Open.

Oscar Tahuahua: Efficacy and Safety of Larotrectinib as First-Line Treatment for Patients with TRK Fusion Cancer

Learn more about Oscar Tahuahua on OncoDaily.

cancer OncoDaily Oncology Oscar Tahuahua TRK Fusion Cancer
Special Coverage
Blog
May 25, 2025, 08:18
Oscar Tahuahua: Efficacy and Safety of Larotrectinib as First-Line Treatment for Patients with TRK Fusion Cancer
Blog
May 25, 2025, 08:11
Manas Dubey: SOFT (Suppression of Ovarian Function Trial) and TEXT (Tamoxifen and Exemestane Trial) Clinical Trials
Blog
May 25, 2025, 07:43
Lao Saal Recaps 7th Swedish Cancer Research Meeting and Showcases Top Talks
Blog
May 25, 2025, 07:04
Wafaa M Rashed: U.S. MAHA Report Lacks Scientific Insight on Childhood Cancer
Science
May 25, 2025, 06:47
Akhil Kapoor: Triple Oral Metronomic Chemotherapy vs Chemotherapy of Physician Discretion After Failure of Platinum-Based Therapy in HNSCC
Dialogues
May 25, 2025, 06:33
Mikhail Grubman on Building Eastern Europe’s Leading CRO and Accelerating Global Oncology Trials
Opinion
May 25, 2025, 06:32
Anastasia Conti Announces Open Research Positions at SR-Tiget in Milan
Blog
May 25, 2025, 06:24
Bernard Fox: TIMO2025 - Great line-up of Immunotherapy Experts
Blog
May 25, 2025, 06:14
Servier's Patients and Doctors Partnership Symposium
Dialogues
May 25, 2025, 06:08
Beyond the Cancer Diagnosis: Dialogue with Wendy Lichtenthal, by Adrian Pogacian
Blog
May 25, 2025, 06:05
International Myeloma Foundation - The Myeloma Minute is Out!
Blog
May 25, 2025, 06:00
The Lancet - A Call to Action: Second Lancet Commission on Adolescent Health and Wellbeing